In addition, in pancreatic neuroendocrine tumors, ATRX/DAXX mutations are considered prognostic biomarkers in patients with poor disease-free survival (DFS), but opposite results in advanced/metastatic patients (Wang et al., 2021), indicating that ATRX mutations at different stages may have different effects and have implications for prognostic judgment. This evidence concerns the gene ATRX and pancreatic neuroendocrine tumor.